Jorge Conde

Jorge Conde is a highly accomplished General Partner at Andreessen Horowitz, with over 20 years of experience in the life sciences and healthcare industries. He has led, built, and invested in numerous early-stage and commercial companies, with expertise in the cross-section of biology, computer science, and engineering. Prior to joining Andreessen Horowitz, Jorge held various executive positions including Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer at Syros, a publicly-traded company advancing small molecules to control the expression of genes. He was also the co-founder and CEO of Knome, a human genome interpretation company that was acquired by Tute Genomics. Before venturing into the startup world, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.

Jorge's educational background is also impressive with an MBA from Harvard Business School, an MS in Biomedical Enterprise Program from Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from The Johns Hopkins University. Over the years, his accomplishments have not gone unnoticed, as he was named one of the top 35 young innovators worldwide by the MIT Technology Review. Jorge is also a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.

At Andreessen Horowitz, Jorge leads investments in innovative companies and serves on the boards of several portfolio companies, including Aria, Asimov, Camp4, Dyno, Earli, EQRx, Komodo Health, Octant Bio, and Tmunity.